5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.02▼ | 6.01▼ | 6.01▼ | 6.03▼ | 5.89▲ |
MA10 | 5.96▼ | 5.96▼ | 5.96▼ | 5.98▲ | 5.70▲ |
MA20 | 5.98▼ | 6.04▼ | 6.06▼ | 5.85▲ | 5.26▲ |
MA50 | 6.08▼ | 6.05▼ | 5.97▼ | 5.64▲ | 6.10▼ |
MA100 | 5.97▼ | 5.74▲ | 5.58▲ | 5.18▲ | N/A |
MA200 | 5.48▲ | 5.29▲ | 5.30▲ | 5.66▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | -0.005▼ | -0.015▼ | -0.002▼ | 0.194▲ |
RSI | 45.443▼ | 45.014▼ | 46.453▼ | 54.266▲ | 53.865▲ |
STOCH | 56.034 | 50.287 | 50.287 | 52.712 | 65.466 |
WILL %R | -67.241 | -70.313 | -70.313 | -62.025 | -24.303▲ |
CCI | -22.508 | -38.695 | -45.737 | 22.607 | 104.028▲ |
Friday, June 13, 2025 11:08 AM
In trading on Friday, shares of Apollo Global Management Inc (new's 7.750% Dep Sh Rate Reset Non-Cumul Pref Shares Ser E (Symbol: ATH.PRE) were yielding above the 7.5% mark based on its quarterly ...
|
Monday, May 26, 2025 05:09 PM
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript ... The first being our positive SER-155 Phase Ib Cohort 2 clinical results. And the second being the sale of VOWST, which ...
|
Thursday, May 08, 2025 01:30 PM
Serina Therapeutics, Inc. announced key developments in its recent press release, highlighting plans for the first patient dosing of SER-252 in a Phase 1b clinical trial for advanced Parkinson's ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 5.79 | 6.15 | 5.772 | 6.00 | 14,000 |
12/06/25 | 6.37 | 6.37 | 5.85 | 5.925 | 8,013 |
11/06/25 | 6.02 | 6.49 | 5.89 | 6.18 | 73,924 |
10/06/25 | 6.10 | 6.19 | 5.92 | 5.92 | 34,498 |
09/06/25 | 5.92 | 6.15 | 5.787 | 6.12 | 5,200 |
06/06/25 | 6.10 | 6.10 | 5.80 | 5.95 | 28,600 |
05/06/25 | 5.90 | 5.999 | 5.80 | 5.95 | 2,300 |
04/06/25 | 5.90 | 5.93 | 5.90 | 5.9198 | 947 |
03/06/25 | 5.9052 | 6.00 | 5.75 | 5.895 | 2,552 |
02/06/25 | 5.9899 | 6.09 | 5.90 | 5.90 | 25,689 |
|
|
||||
|
|
||||
|
|